[{"id":"e5c65e48-a957-4b92-b313-8ca9fc5212ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03435952","created_at":"2021-01-18T16:57:22.872Z","updated_at":"2025-02-25T16:07:34.095Z","phase":"Phase 1","brief_title":"Pembrolizumab with Intratumoral Injection of Clostridium Novyi-NT","source_id_and_acronym":"NCT03435952","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Clostridium novyi-NT"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-10-31"}]